Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 862

1.

Cost-effectiveness of pneumococcal conjugate vaccination in Georgia.

Komakhidze T, Hoestlandt C, Dolakidze T, Shakhnazarova M, Chlikadze R, Kopaleishvili N, Goginashvili K, Kherkheulidze M, Clark AD, Blau J.

Vaccine. 2015 May 7;33 Suppl 1:A219-26. doi: 10.1016/j.vaccine.2014.12.070.

PMID:
25919165
2.

Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.

Vučina VV, Filipović SK, Kožnjak N, Stamenić V, Clark AD, Mounaud B, Blau J, Hoestlandt C, Kaić B.

Vaccine. 2015 May 7;33 Suppl 1:A209-18. doi: 10.1016/j.vaccine.2014.12.043.

PMID:
25919163
3.

Cost-effectiveness analysis of the introduction of the pneumococcal conjugate vaccine (PCV-13) in the Egyptian national immunization program, 2013.

Sibak M, Moussa I, El-Tantawy N, Badr S, Chaudhri I, Allam E, Baxter L, Abo Freikha S, Hoestlandt C, Lara C, Hajjeh R, Munier A.

Vaccine. 2015 May 7;33 Suppl 1:A182-91. doi: 10.1016/j.vaccine.2014.12.044.

PMID:
25919159
4.

Cost-effectiveness analysis of 10- and 13-valent pneumococcal conjugate vaccines in Peru.

Mezones-Holguin E, Canelo-Aybar C, Clark AD, Janusz CB, Jaúregui B, Escobedo-Palza S, Hernandez AV, Vega-Porras D, González M, Fiestas F, Toledo W, Michel F, Suárez VJ.

Vaccine. 2015 May 7;33 Suppl 1:A154-66. doi: 10.1016/j.vaccine.2014.12.039.

PMID:
25919156
5.

Methods and challenges in measuring the impact of national pneumococcal and rotavirus vaccine introduction on morbidity and mortality in Malawi.

Bar-Zeev N, Kapanda L, King C, Beard J, Phiri T, Mvula H, Crampin AC, Mwansambo C, Costello A, Parashar U, Tate JE, Verani JR, Whitney CG, Heyderman RS, Cunliffe NA, French N; VACSURV Consortium.

Vaccine. 2015 Apr 24. pii: S0264-410X(15)00517-4. doi: 10.1016/j.vaccine.2015.04.053. [Epub ahead of print]

6.

Recent Developments and Future Directions of Pneumococcal Vaccine Recommendations.

Tromp KM, Campbell MW, Vazquez A.

Clin Ther. 2015 Apr 23. pii: S0149-2918(15)00185-X. doi: 10.1016/j.clinthera.2015.03.025. [Epub ahead of print] Review.

PMID:
25913921
7.

Cost-effectiveness analysis of the available pneumococcal conjugated vaccines for children under five years in Colombia.

Ordóñez JE, Orozco JJ.

Cost Eff Resour Alloc. 2015 Apr 10;13:6. doi: 10.1186/s12962-015-0032-1. eCollection 2015.

8.

[Pneumococcal vaccination for prevention of pneumonia].

Kwetkat A, Hagel S, Forstner C, Pletz MW.

Z Gerontol Geriatr. 2015 Apr 16. [Epub ahead of print] German.

PMID:
25877774
9.

Differences in homing potentials of Pnc-specific plasmablasts in pneumococcal pneumonia and after PPV and PCV vaccinations.

Palkola NV, Pakkanen SH, Kantele JM, Pakarinen L, Puohiniemi R, Kantele A.

J Infect Dis. 2015 Apr 2. pii: jiv208. [Epub ahead of print]

PMID:
25838267
10.

Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.

Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, van Werkhoven CH, van Deursen AM, Sanders EA, Verheij TJ, Patton M, McDonough A, Moradoghli-Haftvani A, Smith H, Mellelieu T, Pride MW, Crowther G, Schmoele-Thoma B, Scott DA, Jansen KU, Lobatto R, Oosterman B, Visser N, Caspers E, Smorenburg A, Emini EA, Gruber WC, Grobbee DE.

N Engl J Med. 2015 Mar 19;372(12):1114-25. doi: 10.1056/NEJMoa1408544.

PMID:
25785969
11.

Differential impact of pneumococcal conjugate vaccines on bacteremic pneumonia versus other invasive pneumococcal disease.

Ben-Shimol S, Greenberg D, Hazan G, Givon-Lavi N, Gottesman G, Grisaru-Soen G, Dagan R; Israeli Bacteremia and Meningitis Active Surveillance Group.

Pediatr Infect Dis J. 2015 Apr;34(4):409-16. doi: 10.1097/INF.0000000000000604.

PMID:
25764098
12.

Streptococcus pneumoniae Serotypes Identified in Mexican Children with Invasive Disease Before and After the Introduction of PCV7 (1993-2012).

Echaniz-Aviles G, Soto-Nogueron A, Miranda-Novales G, Carnalla-Barajas MN, Velazquez-Meza ME, Solórzano-Santos F; SIREVA Network–Mexico.

Arch Med Res. 2015 Feb;46(2):149-53. doi: 10.1016/j.arcmed.2015.02.004. Epub 2015 Mar 2.

PMID:
25743930
13.

[Pneumococcal vaccination. What is the general practice protocol?].

Füessl HS.

MMW Fortschr Med. 2015 Jan 19;157(1):22. German. No abstract available.

PMID:
25743288
14.

Changing trends of acute otitis media bacteriology in central Israel in the pneumococcal conjugate vaccines era.

Tamir SO, Roth Y, Dalal I, Goldfarb A, Grotto I, Marom T.

Pediatr Infect Dis J. 2015 Feb;34(2):195-9. doi: 10.1097/INF.0000000000000536.

PMID:
25741972
15.

Rates of pneumococcal disease in adults with chronic medical conditions.

Shea KM, Edelsberg J, Weycker D, Farkouh RA, Strutton DR, Pelton SI.

Open Forum Infect Dis. 2014 May 27;1(1):ofu024. doi: 10.1093/ofid/ofu024. eCollection 2014 Mar.

16.

Genetic conjugation of components in two pneumococcal fusion protein vaccines enhances paediatric mucosal immune responses.

Pope C, Oliver EH, Ma J, Langton Hewer C, Mitchell TJ, Finn A.

Vaccine. 2015 Mar 30;33(14):1711-8. doi: 10.1016/j.vaccine.2015.02.012. Epub 2015 Feb 17.

PMID:
25698489
17.

Limited Efficacy of Antibacterial Vaccination Against Secondary Serotype 3 Pneumococcal Pneumonia Following Influenza Infection.

Metzger DW, Furuya Y, Salmon SL, Roberts S, Sun K.

J Infect Dis. 2015 Feb 3. pii: jiv066. [Epub ahead of print]

PMID:
25649173
18.

Tuberculosis as a cause or comorbidity of childhood pneumonia in tuberculosis-endemic areas: a systematic review.

Oliwa JN, Karumbi JM, Marais BJ, Madhi SA, Graham SM.

Lancet Respir Med. 2015 Mar;3(3):235-243. doi: 10.1016/S2213-2600(15)00028-4. Epub 2015 Jan 29. Review.

PMID:
25648115
19.
20.

[Serotype diversity and antimicrobial resistance of Streptococcus pneumoniae].

Maianskiĭ NA, Aliab'eva NM, Lazareva AV, Katosova LK.

Vestn Ross Akad Med Nauk. 2014;(7-8):38-45. Review. Russian.

PMID:
25563003
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk